Charles River Laboratories International, Inc.
CRL
$162.85
-$5.84-3.46%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.11% | -0.85% | -0.92% | -1.21% | -2.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.11% | -0.85% | -0.92% | -1.21% | -2.16% |
| Cost of Revenue | 0.46% | -1.18% | 0.38% | -0.36% | 0.01% |
| Gross Profit | -0.55% | -0.23% | -3.26% | -2.74% | -6.02% |
| SG&A Expenses | -3.06% | 0.58% | 0.59% | 4.40% | -2.79% |
| Depreciation & Amortization | 21.40% | 36.75% | 2.82% | 5.37% | 3.25% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.53% | 0.57% | 0.51% | 0.82% | -0.46% |
| Operating Income | -2.57% | -9.79% | -9.18% | -12.58% | -11.87% |
| Income Before Tax | -649.93% | -206.86% | -104.28% | -103.36% | -94.52% |
| Income Tax Expenses | -67.37% | -37.10% | -36.63% | -50.57% | -45.71% |
| Earnings from Continuing Operations | -684.30% | -662.11% | -118.60% | -114.56% | -105.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.51% | 29.57% | 36.83% | 48.55% | 69.36% |
| Net Income | -630.19% | -750.08% | -119.42% | -115.18% | -105.69% |
| EBIT | -2.57% | -9.79% | -9.18% | -12.58% | -11.87% |
| EBITDA | 3.41% | -0.74% | -8.76% | -2.28% | -8.26% |
| EPS Basic | -492.27% | -1,803.99% | -119.22% | -115.64% | -107.41% |
| Normalized Basic EPS | -24.19% | -8.00% | -19.14% | -17.63% | -17.63% |
| EPS Diluted | -480.62% | -2,050.69% | -119.49% | -115.90% | -107.62% |
| Normalized Diluted EPS | -24.13% | -7.87% | -18.96% | -17.38% | -17.46% |
| Average Basic Shares Outstanding | -4.02% | -3.53% | -2.68% | -1.57% | -0.24% |
| Average Diluted Shares Outstanding | -4.14% | -3.65% | -2.95% | -1.91% | -0.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |